Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) have been given an average recommendation of “Hold” by the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of brokerages have recently commented on CHRS. J P Morgan Chase & Co reissued an “overweight” rating and set a $25.00 price objective (down from $32.00) on shares of Coherus BioSciences in a research report on Tuesday, August 8th. BidaskClub downgraded Coherus BioSciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Maxim Group reissued a “buy” rating and set a $20.00 price objective (down from $40.00) on shares of Coherus BioSciences in a research report on Friday, September 8th. Citigroup reissued a “buy” rating and set a $23.00 price objective on shares of Coherus BioSciences in a research report on Tuesday, November 7th. Finally, ValuEngine downgraded Coherus BioSciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 26th.

Shares of Coherus BioSciences (CHRS) traded down $0.15 during trading on Friday, hitting $8.80. The stock had a trading volume of 318,161 shares, compared to its average volume of 601,414. Coherus BioSciences has a 1-year low of $8.05 and a 1-year high of $29.59. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus BioSciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. sell-side analysts predict that Coherus BioSciences will post -4.39 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in CHRS. Temasek Holdings Private Ltd acquired a new position in Coherus BioSciences in the third quarter valued at approximately $87,524,000. Vanguard Group Inc. boosted its holdings in shares of Coherus BioSciences by 88.8% in the first quarter. Vanguard Group Inc. now owns 2,209,244 shares of the biotechnology company’s stock valued at $46,726,000 after acquiring an additional 1,039,402 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in shares of Coherus BioSciences by 54.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock valued at $19,964,000 after acquiring an additional 490,899 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in shares of Coherus BioSciences by 70.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,001,104 shares of the biotechnology company’s stock valued at $14,366,000 after acquiring an additional 414,229 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Coherus BioSciences in the second quarter valued at approximately $4,850,000. 81.07% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Coherus BioSciences, Inc. (CHRS) Receives Average Recommendation of “Hold” from Analysts” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/01/coherus-biosciences-inc-chrs-receives-average-recommendation-of-hold-from-analysts.html.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.